Teva settles with Gilead on HIV treatment patent litigation

Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

Gilead Sciences, Inc. (Nasdaq: GILD) announced that it has reached an agreement in principle to settle the ongoing patent litigation with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

Gilead president and COO said, “We believe strongly in the validity of our intellectual property. This settlement, however, removes some uncertainty and minimizes further distraction and investment of human and financial resources associated with this litigation.”

The trial in this litigation, which was scheduled to begin on Wednesday, February 20 in the District Court for the Southern District of New York, has been adjourned pending completion of activities necessary to finalize the settlement.

Published by Globes [online], Israel business news - www.globes-online.com - on February 21, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters